Insider · CIK 0001605411
Peter Clausen
Files at AURX (Nuo Therapeutics, Inc.). First filing -, latest -.
In brief
Peter Clausen files SEC Form 4 as COO at AURX (Nuo Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Peter Clausen has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | AURX Nuo Therapeutics, Inc. | AGrant or award Option to purchase common stockderivative | +65,000 | $0.00 | $0 | 65,000 | Jul 2, 2026 |
| Jul 31, 2025 | AURX Nuo Therapeutics, Inc. | MOption exercise Common Stock | +183,853 | $0.40 | $74k | 770,054 | Aug 4, 2025 |
| Aug 9, 2018 | AURX Nuo Therapeutics, Inc. | MOption exercise Option to purchase common stockderivative | -183,853 | $0.00 | $0 | 0 | Aug 4, 2025 |
| Dec 19, 2023 | AURX Nuo Therapeutics, Inc. | AGrant or award Common Stock | +20,000 | $0.50 | $10k | 571,201 | Dec 20, 2023 |
Questions about Peter Clausen
Answered from the filings on this page, as of the latest one.
Is Peter Clausen buying or selling?
Peter Clausen has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Peter Clausen's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Peter Clausen has 0.
Where does Peter Clausen file Form 4?
Peter Clausen has filed Form 4 at AURX (Nuo Therapeutics, Inc.) as CSO/COO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.